# Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

> **NCT01581970** · PHASE2 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 7 (actual)

## Conditions studied

- Head and Neck Cancer
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT01581970
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2019-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01581970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01581970, "Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01581970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*